BN Business News
Ajouter votre entreprise →
Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.

Entreprise · 30/07/20091 min de lecture

Guidance for Industry on Drug-Induced Liver Injury: Premarketing Clinical Evaluation; Availability

Traduction automatique locale · Langue originale de la source

Résumé

The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled "Drug-Induced Liver Injury: Premarketing Clinical Evaluation." This guidance is intended to assist the pharmaceutical industry and others engaged in new drug development in the assessment of the potential of a drug to cause severe drug-induced liver injury (DILI) during the conduct of premarketing trials. This guidance defines severe DILI as injury that is fatal or requires liver transplantation.

Langue originale de la source: Federal Register — Food and Drug AdministrationOuvrir le communiqué original →

Explorer les analyses

Analyses business →